Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5688372 | 0.81 | SGMS2 (0.40) | SGMS2KDM4E | |
| SCHEMBL29709962 | 0.81 | SGMS2 (0.40) | SGMS2KDM4E | |
| SCHEMBL18292000 | 0.81 | HIF1A (0.38) | HIF1ASGMS2 | |
| SCHEMBL30368058 | 0.81 | HIF1A (0.38) | HIF1ASGMS2 | |
| SCHEMBL20822846 | 0.81 | MAPK8 (0.47) | SGMS2KDM4EALDH1A1 | |
| SCHEMBL29470271 | 0.81 | HPGD (0.43) | KDM4EALDH1A1 | |
| SCHEMBL30367824 | 0.78 | SGMS2 (0.42) | HIF1ASGMS2 | |
| SCHEMBL18291950 | 0.78 | SGMS2 (0.42) | HIF1ASGMS2 | |
| SCHEMBL7171950 | 0.78 | MAPK1 (0.41) | HIF1AKDM4EALDH1A1 | |
| SCHEMBL7171946 | 0.78 | MAPK1 (0.41) | HIF1AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123440-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-20 | — | — | US | disclosed |
| US-20190082687-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123440-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | DDT, MLEC, MSMO1 | HCRTR1 1430/4885HCRTR2 2112/4885PLCG1 267/4885 |
| US-20190082687-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | DDT, MLEC, MSMO1 | HCRTR1 1430/4885HCRTR2 2112/4885PLCG1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.